GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome
Go back to GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 14.88 -0.42 (2.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.30 | 52 Week High | $117.12 | |||
| Open | $15.10 | 52 Week Low | $46.52 | |||
| Day High | $15.25 | P/E | N/A | |||
| Day Low | $14.63 | EPS | $-1.97 | |||
| Volume | 5,921,941 | |||||
